Navigation Links
Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
Date:4/21/2009

vestigators, the data suggests that the PI3-K/Akt/ B-catenin pathway plays an important role in mammary stem cell self-renewal and that targeting of cancer stem cells through inhibition of this signaling pathway represents a rational therapeutic strategy.

Abstract 4576:

Potent antitumor effects of nab-rapamycin (ABI-009) in combination with kinase inhibitors Erlotinib and Perifosine

Author(s): Neil Desai, Osmond D'Cruz, Vuong Trieu. Abraxis BioScience, LLC., Los Angeles, CA

Time/location: 1:00 PM - 5:00 PM, Hall B-F, Poster Section 33, # 9

Abstract Summary: According to Investigators, this study confirmed results by Cirstea et al. that dual inhibition of the Akt pathway by rapamycin (ABI-009) and Perifosine induces synergistic anti-tumor activity in multiple myeloma (AACR Annual Meeting 2008, #4181). The synergy of these combinations confirms Investigators' hypothesis that rapamycin is active only on mTORC1 and inhibition of mTORC2 by either Erlotinib or Perifosine is necessary to achieve complete shutdown of mTOR signaling pathway.

The following abstract was presented yesterday:

Abstract 2822:

Evidence implicating Bim activation/induction in potentiation of PI3K/Akt inhibitor-mediated apoptosis in human leukemia cells

Author(s): Mohamed Rahmani, Anh Anderson, Joseph Reza Habibi, Timothy Ryan Crabtree, Hisashi Harada, Paul Dent, Steven Grant. VCU Massey Cancer Ctr., Richmond, VA

Abstract Summary: Investigators conclude that findings from this study suggest that Bim activation plays a key role in potentiating the antineoplastic activity of PI3K/Akt inhibitors in human leukemia cells, and raise the possibility that this phenomenon may contribute to synergistic interactions between PI3K/Akt and MEK1/2 inhibitors in such cells.

All abstracts can be viewed at

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and NEW YORK , ... PTBI, PTBIW), a biopharmaceutical company advancing patient care in ... offering of 3,500,000 shares of common stock, and warrants ... common stock, at an offering price of $4.00 per ... per share exercise price of $5.00, are exercisable immediately, ...
(Date:12/24/2014)... Earlier this year in a June 24 international ... Adult Stem Cell Technology Center, LLC ( ASCTC ) ... unique property of adult tissue stem cells. His ... the Past, Important for the Future,” embodied the essence ... the address at the 4th World Congress on Cell ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. George ... Society for Reproductive Medicine (ASRM), a leading professional organization ... In his new role as treasurer, Dr. Hill ... will have a voice in furthering the mission of ... since 1984 when he joined while conducting fellowship training ...
(Date:12/24/2014)... PharmaBoardroom,s new report, , Healthcare and ... free download , digs deep into this vibrant market, ... sector today. One area where Algeria ... a homegrown pharmaceutical manufacturing base, even if the government,s ambitious ... off. A cursory comparison with neighboring Morocco ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3
... Second Quarter and Six-Month Results -- NEW YORK, Aug. 19 /PRNewswire-Asia/ -- ... ... ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... and CAMBRIDGE, Massachusetts, August 19, 2010, ... ... var shortURL ... by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... an improved coating technique that could strengthen the connection ... The stronger connection -- created by manipulating signals the ... allow the implants to last longer. Implants coated ... mimics the body,s own cell-adhesion material fibronectin made 50 ...
Cached Biology Technology:Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 2Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 3Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 4Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 5Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 6Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 7Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 8Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 9Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 10Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 11Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 12Broad Institute Acquires License to all ChemAxon products and Deploys Across Chemical Biology Platform 2Broad Institute Acquires License to all ChemAxon products and Deploys Across Chemical Biology Platform 3Broad Institute Acquires License to all ChemAxon products and Deploys Across Chemical Biology Platform 4Broad Institute Acquires License to all ChemAxon products and Deploys Across Chemical Biology Platform 5Broad Institute Acquires License to all ChemAxon products and Deploys Across Chemical Biology Platform 6Titanium coating with protein 'flower bouquet' nanoclusters strengthens implant attachment 2Titanium coating with protein 'flower bouquet' nanoclusters strengthens implant attachment 3
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
(Date:12/3/2014)... 2, 2014 As part of our commitment ... is pleased to announce the release of a new ... collect the workforce data that they need. ... left by existing readers. Many such devices have serious ... modern technology. Older models force users to navigate numerous ...
(Date:11/21/2014)... -- C-Labs LLC, a leading provider of remote and ... announced the appointment of John Traynor to ... advisor to the firm, Mr. Traynor will now oversee ... out of the C-Labs office in Redmond, ... , Chief Executive Officer. Photo - ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... Medical Biology (IMB) scientists under the Agency of Science, ... an international team of researchers [1]who became the first ... rare skin cancer which grows rapidly for a few ... Nature Genetics [2] today. The peculiar ...
... requires an increasingly interdisciplinary perspective. Presenters at the National ... 2 will discuss ways to identify, encourage, and support ... in this and other fields. In ... the 11th annual Sackler Lecture beginning at 6 p.m. ...
... neurosurgery to bar code readers, lasers have been used in ... the late 1950,s. Now, with the work being done in ... way to use lasers to study the splicing of pre-messenger ... advanced organisms, including human life. This process of splicing is ...
Cached Biology News:Scientists discover cause of rare skin cancer that heals itself 2Brandeis researchers use lasers, custom microscope to show gene splicing process in real time 2Brandeis researchers use lasers, custom microscope to show gene splicing process in real time 3
... years of expertise in the field of ... the most powerful systems on the market. ... 000 in-microplate tests requiring incubation and washing ... modules (such as worktable shaker incubators, reader,washer), ...
... pre-validated SNP sequencing services ... within 93 genes including ... more than 80 tyrosine ... were developed and validated ...
... Mouse anti-Yersinia pestis F1 antigen, ... Applications: ELISA: Use at ... at an assay dependent dilution. WB: ... Predicted molecular weight: 18 kDa. Not ...
... Fixation medium Reagent B - Permeabilisation medium ... cells in suspension with Reagent A and ... This procedure gives antibodies access to intracellular ... of the cells intact. Specific formulations reduce ...
Biology Products: